India markets open in 6 hours 34 minutes
  • BSE SENSEX

    52,578.76
    -273.51 (-0.52%)
     
  • Nifty 50

    15,746.45
    -78.00 (-0.49%)
     
  • Dow

    35,058.52
    -85.79 (-0.24%)
     
  • Nasdaq

    14,660.58
    -180.14 (-1.21%)
     
  • BTC-INR

    2,839,125.00
    +29,054.00 (+1.03%)
     
  • CMC Crypto 200

    898.78
    +22.55 (+2.57%)
     
  • Hang Seng

    25,086.43
    -1,105.89 (-4.22%)
     
  • Nikkei

    27,970.22
    +136.93 (+0.49%)
     
  • EUR/INR

    88.1373
    +0.3614 (+0.41%)
     
  • GBP/INR

    103.4688
    +0.7416 (+0.72%)
     
  • AED/INR

    20.2390
    +0.0460 (+0.23%)
     
  • INR/JPY

    1.4694
    -0.0127 (-0.86%)
     
  • SGD/INR

    54.7740
    +0.0440 (+0.08%)
     

Govt expert panel accepts Covaxin phase-3 trial data

·1-min read

New Delhi, Jun 22 (PTI) An expert panel of the country's central drugs authority has reviewed and accepted the phase-3 trial data of Bharat Biotech's COVID-19 vaccine Covaxin, sources said on Tuesday.

According to the data submitted by the Hyderabad-based firm, the indigenously developed vaccine has shown 77.8 per cent efficacy in the trial conducted on 25,800 subjects, they said.

The firm had submitted the results of its phase-3 trial efficacy data of Covaxin to the Drugs Controller General of India (DCGI) over the weekend, they added.

The COVID-19 Subject Expert Committee (SEC) of the Central Drugs Standard Control Organisation (CDSCO) on Tuesday reviewed the data and accepted it. Their recommendations have been sent to the DCGI now, a source said.

Bharat Biotech is also expected to attend a 'pre-submission' meeting on July 23 with the World Health Organisation (WHO), which will take the vaccine-maker closer to a WHO Emergency Use Listing (EUL).

Though the meeting will not be a detailed review on the product, the vaccine-maker will have an opportunity to submit a summary on the overall quality of the jab, according to the WHO.

The information was provided on the WHO website in the Status of COVID-19 Vaccines within WHO EUL-PQ evaluation process document.

Covaxin is one of the three vaccines approved by the DGCI for emergency use and is being deployed in India's COVID-19 vaccination programme. PTI PLB TIR TIR

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting